Spruce Biosciences Inc (NAS:SPRB)
$ 0.4111 0.0156 (3.94%) Market Cap: 16.34 Mil Enterprise Value: -40.49 Mil PE Ratio: 0 PB Ratio: 0.32 GF Score: 32/100

Spruce Biosciences Inc at RBC Capital Markets Global Healthcare Conference Transcript

May 17, 2023 / 07:05PM GMT
Release Date Price: $2.3 (+4.55%)
Greg Renza
RBC Capital Markets - Analyst

Welcome back everyone to the 2023 RBC Global Healthcare Conference. My name is Greg Renza, one of the senior biotechnology equity research analysts here at RBC. And we're pleased to be joined now by Spruce Biosciences and representing the company is the Chief Executive Officer, Javier Szwarcberg.

Javier, it's great to see you. I think the best way to kick this off is the pitch it over to you just to give an introduction and brief intro on Spruce.

Javier Szwarcberg
Spruce Biosciences, Inc. - CEO

Perfect, Greg. Thank you so much. Thank you, RBC, and thank you for having me here today.

So Spruce is a biotechnology company focused on developing compounds for rare endocrine disorders. We're currently focusing primarily on CAH, which stands for congenital adrenal hyperplasia. It is a disease for which there is a significant unmet need, a disease for which not only compounds have actually been -- actually there's no approved compound and there's not a lot of research going on at the moment. Overall

Already have an account? Log in
Get the full story
Access to All Earning Calls and Stock Analysis
30-Year Financial on one screen
All-in-one Stock Screener with unlimited filters
Customizable Stock Dashboard
Real Time Insider Trading Transactions
8,000+ Institutional investors’ 13F holdings
Powerful Excel Add-in and Google sheets Add-on
All data downloadable
Quick customer support
And much more...
30-Day 100% money back guarantee
You are not charged until the trial ends. Subscription fee may be tax deductible.
Excellent
4.6 out of 5 Trustpilot